CORCEPT THERAPEUTICS INC
CORTNASDAQTrading Snapshot
- Day Range
- $113.80 – $116.05
- 52-Week Range
- $28.66 – $126.38
- Volume
- $3.47B
- Avg Volume
- $4.28B
- Shares Outstanding
- 108.1M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $761M
- Last Q Revenue
- $256M
- P/E Ratio
- 225.6
- P/S Ratio
- 15.0x
- EPS (TTM)
- $0.43
- Dividend Yield
- —
- Dilution (1yr)
- +1.2%
Why Investors Own CORT
- ✓High-growth profile — revenue up +14.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CORCEPT THERAPEUTICS INC
CORT
StockOtter · stockotter.spaceAbout CORCEPT THERAPEUTICS INC
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Corcept Announces Planned Leadership Transition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $29,842.72 in Stock
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Corcept Grows to Mid-Cap on Institutional Support
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.